Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUT014 in EGFR Inhibitor Induced Acneiform Lesions
NCT03876106Phase 1Completed
- Sponsor
- Lutris Pharma
- Start
- Aug 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of LUT014 in acneiform rash (3 arms), sponsored by Lutris Pharma. Primary endpoint: Safety and tolerability (maximum tolerated dose, MTD). Started Aug 2019; status: completed.
02
Drugs
LUT014
03
Conditions
acneiform rash
Beyond the preview
Go deeper on NCT03876106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03876106.